However, the risk of conversion from adenoma to carcinoma may be greater in MLH1/MSH2 gene mutation carriers, perhaps due to higher ID mutation rates that supervene once the wild-type MMR gene allele is lost in individual cells. The gene discussed is MLH1; the disease is carcinoma.